Hi {{lead.First Name:default=edit me}},

If you need human biospecimens from patients with confirmed disease, consider the numbers 4, 7, and 35.

Four weeks is the typical request-to-receipt turnaround time when you predefine one or several patient communities for dependable access to blood, PBMC, or other in-home, prospectively collected biospecimens. With IRBs, consent, and startup operations completed in advance, you can get fresh samples when you need them.

7 is the number of different disease states Sanguine has targeted in our previous work with Genentech. Many of these studies involved specific I/E criteria, so you know we can deliver.

35 is the number of pre-approved conditions that we can collect leukopaks from to cater to your team’s needs for B, T, and NK cells to accelerate your validation, development, and process development efforts. 

Given our past success working together, you know that having qualified patient samples ready for biomarker identification, first-in-human feasibility, and assay development can shorten timelines and reduce costs. Let’s discuss whether a tailored patient access model makes sense for your research program.

Warm Regards,

Lisl Mayer
Research Consultant
Sanguine Bio | Massachusetts

Schedule a Meeting
| www.sanguinebio.com